
Release date: 2026-01-08 10:10:03 Article From: Lucius Laos Recommended: 143
Ixazomib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma.
Immediately inform your doctor if you experience burning, numbness, tingling, or pain in your arms, hands, legs, or feet. These could be symptoms of peripheral neuropathy.
This product may cause fluid retention (edema) in some patients. Promptly notify your doctor if you notice swelling of the face, arms, hands, lower legs, or feet, tingling sensations in hands or feet, or abnormal weight gain or loss.
Seek medical attention as soon as possible if you develop skin rash, erythema, or skin discoloration.
Thrombotic microangiopathy (damage to small blood vessels) may occur during the administration of this product. Immediately tell your doctor if you have symptoms such as fever, fatigue, confusion, visual impairment, or seizures.
Seek immediate medical care if you experience upper abdominal pain or tenderness, clay-colored stools, dark urine, anorexia, nausea, vomiting, or jaundice (yellowing of the eyes or skin). These may be symptoms of severe hepatic disorders.
Do not take other medications concurrently without your doctor’s approval, including prescription drugs, over-the-counter drugs, herbal preparations (e.g., St. John’s Wort), or vitamin supplements.
1. Store at room temperature, not exceeding 30°C (86°F).
2. Do not freeze.
3. Keep the capsules in the original packaging until immediately prior to administration.
4. Avoid direct contact with the contents of the capsules. If a capsule is damaged, do not allow the drug to come into direct contact with skin or eyes.
5. In case of skin contact, wash the affected area thoroughly with soap and water.
6. In case of eye contact, rinse the eyes thoroughly with clean water.
7. Dispose of any unused medication or waste materials in accordance with local regulations.
Inform your healthcare provider if you have any of the following conditions:
1. Renal disease.
2. Hepatic disease.
3. A history of abnormal or allergic reactions to ixazomib, other medications, foods, dyes, or preservatives.
4. Are pregnant or planning to become pregnant.
5. Are breastfeeding.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643